Updated hourlyHourly refreshMon, Sep 14, 2026
Press Release Database
Recent press releases, indexed by topic.
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Flotek Industries, Inc. (NYSE:FTK) securities. If you suffered a loss on your Flotek Industries, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Flotek Industries, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed ..
Sep 11 · 17:32·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Replimune Group, Inc. (NASDAQ:REPL) securities. If you suffered a loss on your Replimune Group, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Replimune Group, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed ..
Sep 11 · 17:30·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Unicycive Therapeutics, Inc. (NASDAQ:UNCY) securities. If you suffered a loss on your Unicycive Therapeutics, Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Unicycive Therapeutics, Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed ..
Sep 11 · 17:27·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Wise Group plc (NASDAQ:WSE) securities. If you suffered a loss on your Wise Group plc investment and would like to explore a potential recovery under the federal securities laws, Learn about Wise Group plc Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed ..
Sep 11 · 17:27·PR-Inside
Finance
Company completes 104.8-ton bulk-sampling program at Skaergaard; advances geological mapping and environmental baseline studies at Sarfartoq Company completes 104.8-ton bulk-sampling program at Skaergaard; advances geological mapping and environmental baseline studies at Sarfartoq
Sep 11 · 17:27·GlobeNewswire
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Park Ha Biological Technology Co., Ltd. (NASDAQ:BYAH) securities. If you suffered a loss on your Park Ha Biological Technology Co., Ltd. investment and would like to explore a potential recovery under the federal securities laws, Learn about Park Ha Biological Technology Co., Ltd. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder ..
Sep 11 · 17:22·PR-Inside
Finance · Healthcare
(PR-inside.com) LOS GATOS, CA / ACCESS Newswire / September 11, 2026 / Tenon Medical, Inc. (NASDAQ:TNON) ("Tenon" or the "Company"), a medical device company dedicated to transforming care for patients with certain sacro-pelvic disorders announced today it has entered into warrant exercise agreements with an institutional investor to exercise outstanding warrants to purchase an aggregate of 572,179 of the Company's shares of common stock (the "Existing Warrants"). In consideration for the immediate exercise in full of the Existing Warrants for gross cash proceeds of $2,872,338.58, the exercising holders will receive in a private placement new unregistered warrants (the "New Warrants") to ..
Sep 11 · 17:22·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) securities. If you suffered a loss on your ARS Pharmaceuticals investment and would like to explore a potential recovery under the federal securities laws, Learn about ARS Pharmaceuticals Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against ARS ..
Sep 11 · 17:15·PR-Inside
Finance · AI
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Datavault AI Inc. (NASDAQ:DVLT) securities. If you suffered a loss on your Datavault AI Inc. investment and would like to explore a potential recovery under the federal securities laws, Learn about Datavault AI Inc. Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed ..
Sep 11 · 17:15·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Levi & Korsinsky, LLP announces that a securities class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Planet Fitness, Inc. (NYSE:PLNT) securities. If you suffered a loss on your Planet Fitness investment and would like to explore a potential recovery under the federal securities laws, Learn about Planet Fitness Class Action or contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or call (212)363-7500 to speak to our team of experienced shareholder advocates. THE LAWSUIT: A class action securities lawsuit was filed against Planet ..
Sep 11 · 17:03·PR-Inside
Finance · Media
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Novartis AG ("Novartis" or "the Company") (NYSE:NVS). Investors who purchased Novartis securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/novartis-ag-nvs-class_action_lawsuit. Novartis Investigation Details On September 8, 2026, Novartis issued a press release "announcing that the global Phase III HARBOR study evaluating del-desiran in people living with myotonic dystrophy type 1 (DM1) did not demonstrate statistically significant improvement versus placebo on the primary endpoint of video hand opening time ..
Sep 11 · 17:03·PR-Inside
Finance
(PR-inside.com) NEW YORK CITY, NY / ACCESS Newswire / September 11, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or "the Company") (NASDAQ:RARE). Investors who purchased Ultragenyx securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/cases/ultragenyx-pharmaceutical-inc-rare-class_action_lawsuit. Ultragenyx Investigation Details On September 2, 2026, Ultragenyx issued a press release "announcing results from the Phase 3 Aspire study for apazunersen (GTX-102) in Angelman syndrome." Per the press release, "[t]he study did not achieve the primary endpoint of change from Baseline in Bayley-4 cognitive raw score ..
Sep 11 · 17:03·PR-Inside